2.55

2.12% -0.05

Cabaletta Bio Inc (CABA)

Overview News Price History Option Chain Financials Why CABA Down? Discussions Forecast

Cabaletta Bio Inc stock is traded at $2.55, with a volume of 855.71K. It is down -2.12% in the last 24 hours and down -5.39% over the past month. Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Previous Close:

$2.60

Open:

$2.6

24h Volume:

855.71K

Relative Volume:

0.35

Market Cap:

$127.08M

Revenue:

Net Income/Loss:

$-67.68M

P/E Ratio:

-1.5361

EPS:

-1.66

Net Cash Flow:

$-54.24M

1W Performance:

+6.49%

1M Performance:

-5.39%

6M Performance:

-58.35%

1Y Performance:

-89.21%

1-Day Range:

$2.54

$2.76

1-Week Range:

$2.21

$2.76

52-Week Range:

$1.76

$26.35

Cabaletta Bio Inc Stock (CABA) Company Profile

Name

Cabaletta Bio Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

(267) 759-3100

Address

2929 ARCH STREET, PHILADELPHIA, PA

Employee

154

Twitter

@CabalettaBio

Next Earnings Date

2024-11-07

Latest SEC Filings

CABA's Discussions on Twitter

Compare CABA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CABA Cabaletta Bio Inc	2.5469	127.08M	0	-67.68M	-54.24M	-1.66
VRTX Vertex Pharmaceuticals Inc	474.30	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.08	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	653.05	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	275.28	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.71	28.75B	3.30B	-501.07M	1.03B	-2.1146

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-10-24	Initiated	UBS	Buy
Feb-05-24	Initiated	Jefferies	Buy
Nov-29-23	Initiated	William Blair	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	Stifel	Buy
Sep-05-23	Initiated	Citigroup	Buy
Jul-18-23	Initiated	Guggenheim	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jun-30-21	Initiated	Mizuho	Buy
Jan-08-21	Initiated	Chardan Capital Markets	Buy
Oct-13-20	Initiated	H.C. Wainwright	Buy
Nov-19-19	Initiated	Cowen	Outperform
Nov-19-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Morgan Stanley	Overweight

View All

Cabaletta Bio Inc Stock (CABA) Latest News

11:50 AM

Company’s Banking Stock: Dissecting a -35.00% Quarterly Revenue Decline Amid Growth - The InvestChronicle

11:50 AM

Feb 06, 2025

Does Cabaletta Bio Inc (CABA) offer a good opportunity for investors? - SETE News

Feb 06, 2025

Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Sold by Jennison Associates LLC - MarketBeat

Feb 06, 2025